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Duchenne muscular dystrophy (DMD†) is an X-chromosome-linked disorder and the most common 
monogenic disease in people. Affected boys are diagnosed at a young age, become non-ambulatory by 
their early teens, and succumb to cardiorespiratory failure by their thirties. Despite being a monogenic 
condition resulting from mutations in the DMD gene, affected boys have noteworthy phenotypic 
variability. Efforts have identified genetic modifiers that could modify disease progression and be 
pharmacologic targets. Dogs affected with golden retriever muscular dystrophy (GRMD) have absent 
dystrophin and demonstrate phenotypic variability at the functional, histopathological, and molecular 
level. Our laboratory is particularly interested in muscle metabolism changes in dystrophin-deficient 
muscle. We identified several metabolic alterations, including myofiber type switching from fast (type 
II) to slow (type I), reduced glycolytic enzyme expression, reduced and morphologically abnormal 
mitochondria, and differential AMP-kinase phosphorylation (activation) between hypertrophied and 
wasted muscle. We hypothesize that muscle metabolism changes are, in part, responsible for phenotypic 
variability in GRMD. Pharmacological therapies aimed at modulating muscle metabolism can be tested 
in GRMD dogs for efficacy.
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INTRODUCTION
Duchenne muscular dystrophy (DMD) occurs in ap-
proximately 1 in 5,000 boys, resulting from out-of-frame 
mutations in the DMD gene that lead to loss of dystro-
phin protein and its glycoprotein complex [1].Disruption 
of these scaffolding and signaling molecules leads to 
myofiber instability and progressive muscle wasting and 
weakness, with patients losing ambulation by their early 
teens and succumbing to the condition by their thirties. A 
milder, allelic form of dystrophinopathy, Becker muscu-
lar dystrophy (BMD), results from in-frame DMD gene 
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mutations that allow production of a truncated, partially 
functional protein [2,3]. Becker patients usually live and 
ambulate for several additional decades [4]. In addition 
to the pathologic changes directly caused by dystrophin 
deficiency, so-called genetic modifiers and secondary ef-
fects contribute to further phenotypic variation. Studies in 
the DMD animal models, X-linked muscular dystrophy 
(mdx) mouse [5] and golden retriever muscular dystro-
phy (GRMD) dog [6], have played an important role in 
defining the potential basis for this variability. Based on 
gene and protein studies, reduced glycolytic and oxida-
tive enzyme expression and activity, a so-called “meta-
bolic crisis,” contributes to differential involvement of 
both individuals and muscles [7-11]. These metabolic 
changes may be more pronounced in DMD and GRMD 
versus the mdx mouse, perhaps contributing to the more 
severe phenotype of dystrophin deficient boys and dogs. 
As such, the GRMD canine model appears to be a suit-
able animal model for muscle metabolism changes and 
response to respective therapy.
In this study, we evaluated the metabolic chang-
es that occur in the GRMD dog. We hypothesized that 
GRMD muscle undergoes similar metabolic changes 
seen in DMD and mdx, including fiber type switching, re-
duced glycolytic and oxidative metabolism, defective mi-
tochondria, and molecular aberrations. We show for the 
first time a molecular compensatory mechanism involv-
ing AMP-kinase (AMPK), which may drive hypertrophy 
versus wasting with regards to muscle metabolism.
METHODS
Animals. The dogs were used and cared for accord-
ing to principles outlined in the National Research Coun-
cil’s Guide for the Care and Use of Laboratory Animals. 
They were maintained at North Carolina State Universi-
ty, University of Missouri, University of North Carolina, 
and then at Texas A&M University. Historical data for 
each dog in the colony were stored in Breeder’s Assistant 
(Tenset Technologies, Ltd; United Kingdom), including 
genotype, date of birth, date of death, and any other de-
fining information.
Surgical Muscle Biopsies. Biopsy samples from the 
cranial sartorius (CS), long digital extensor (LDE), and 
vastus lateralis (VL) muscles were collected surgically, 
snap frozen in liquid nitrogen-cooled SUVA34A (a Freon 
analog; DuPont Fluorochemicals, Wilmington, DE), and 
subsequently archived at -80°C until analysis.
Functional Outcome Measures. Surgically measured 
CS muscle circumference, a directly measure of muscle 
size was performed, as previously described [8].
Light Microscopy. Muscle sample processing, hema-
toxylin, and eosin (H&E) staining, and light microscopic 
analysis were performed, also as previously described 
[8].
Immunofluorescence Microscopy. Muscle samples 
were stored at -80°C prior to processing. For immunoflu-
orescence, serial muscle cryosections were cut at 7 μm, 
thawed on Superfrost Plus slides (Fisher Scientific, Pitts-
burgh, PA), rehydrated and permeabilized in physiologi-
cal buffered saline (PBS) containing 0.2 percent fish skin 
gelatin (FSG) and 0.1 percent Triton X-100 for 10 minutes 
at room temperature (~20°C). Samples were washed two 
times with PBS. Sections were fixed in cold, 100 percent 
acetone for 10 minutes and then washed three times with 
PBS (5 minutes each). Samples were blocked for 1 hour 
at ~20°C with 5 percent normal goat serum, PBS+0.3 per-
cent Triton X-100. Primary antibody incubation occurred 
overnight (~17 hours) at 4°C with the following antibod-
ies: mouse monoclonal myosin heavy chain (fast twitch) 
(NCL-MHCF; Leica Biosystems, Buffalo Grove, IL) and 
mouse monoclonal myosin heavy chain (slow twitch) 
(NCL-MHCS; Leica Biosystems, Buffalo Grove, IL). 
Sections were then washed two times in PBS-FSG-Tri-
ton (5 minutes each) and then once with PBS-FSG. Sec-
ondary antibody incubation was for 1 hour at ~20°C with 
goat anti-mouse Alexa Fluor® 594 (A11005; Thermo 
Fisher, Waltham, MA). Samples were washed two times 
with PBS-FSG-Triton and then incubated with DAPI (for 
DNA) for 5 minutes at 20°C. Prolong® Gold Anti-fade 
reagent (Life Technologies, Carlsbad, CA) was placed on 
the sections followed by coverslips. Images of the sec-
tions were viewed on a Nikon Eclipse 80i microscope and 
collected for analysis with NIS-Elements Basic Research 
software (Laboratory Imaging, Version 3.22.14). Further 
Figure 1. Phenotypic variation was observed in 
DMD boys. Left: Mildly affected DMD patient. Note the 
apparent leg musculature enlargement. Right: Severely 
affected DMD boy with muscle wasting and weakness in 
the arms and legs. Note the boy needed assistance to 
stand. Photos courtesy of L.B.
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imaging processing was performed in ImageJ software 
(National Institute of Health, Version 1.48).
Transmission Electron Microscopy (TEM). Cranial 
sartorius and VL muscle samples were collected at nec-
ropsy from 6- to 12-month old GRMD and normal dogs 
and routinely prepared for TEM. Samples were fixed im-
mediately in 3 percent glutaraldehyde + 2 percent para-
formaldehyde buffered with 0.1 M sodium cacodylate 
(pH 7.4) for 1 hour. Individual muscle fascicles were 
dissected from each muscle sample and placed in fresh 
fixative overnight at 4°C. Muscle fascicles were then re-
moved from the fixative and washed with 0.1 M sodi-
um cacodylate solution. Following fixation, tissues were 
treated with 2 percent OsO4+1.5 percent K Ferrocyanide 
in 0.1 M sodium cacodylate for 5 hours at room tempera-
ture. Next, tissues were washed three times with water 
for 5 minutes each and then incubated with 2 percent 
uranyl acetate in distilled water for 3 hours. Following 
uranyl acetate treatment, the tissue was washed overnight 
in water at room temperature and three times with wa-
ter prior to dehydration. Tissues were dehydrated using 
a graded series of absolute ethanol solutions, finishing 
with absolute acetone, and then incubated overnight with 
1/3 EMbed 812 Resin (Electron Microscopy Sciences, 
Hatfield, PA) and 2/3 absolute acetone at room tempera-
ture. Next, samples were incubated with 2/3 Resin and 
1/3 absolute acetone at room temperature for 8 hours 
and then overnight in 100 percent Resin. Finally, tissues 
were placed in molds, embedded in Resin, and baked at 
60°C for ~72 hours. Thin sections (80 nm) were placed 
on formvar-coated mesh grids and copper mesh grids for 
staining with uranyl acetate and lead citrate. Images were 
collected from an FEI Transmission Electron Microscope 
in the Image Analysis Laboratory at Texas A&M Univer-
sity and digitally captured for analysis. Further imaging 
processing was performed in ImageJ.
Protein Extraction and Western Blot Analysis. Stain-
free BioRad gels (12 percent, 1.5mm) were prepared 
using the TGX Stain-Free Fast Cast Acrylamide Start-
er Kit. Muscle tissue from normal and GRMD CS and 
LDE samples at 6 months of age were homogenized and 
quantified, as previously described [12]. One hundred μg 
of protein was mixed with Laemmli two times electro-
phoresis buffer until the total volume reached (20 μL). 
The samples were heated at 95°C for 4 minutes, and then 
each sample was loaded into the gel along with 10 μL 
of Novex Sharp prestained ladder (Invitrogen; Carlsbad, 
CA). Duplicate samples were loaded into two separate 
gels, which were electrophoresed for 35 minutes at 200 
V and then a picture was taken using BioRad ImageLab 
4.1 and Gel Doc EZ (Hercules, CA). The proteins were 
transferred to two separate PVDF membranes for 1 h at 
100 V. The membranes were blocked in 5 percent bovine 
serum albumin (BSA) and 0.1 percent tween TBST at 
4°C overnight. Membranes were then vigorously washed 
three times with 0.1 percent tween in TBST for 5 minutes 
at room temperature. AMPKα-rabbit antibody (detects 
total AMPKα1 and α2 subunits; Cell Signaling Tech-
nology #2532; Danvers, MA), at a dilution of 1:1,000 
in 5 percent BSA/TBST, was applied to one membrane. 
PhosphoAMPKα-rabbit antibody (detects both phos-
phorylated AMPKα1 and α2 subunits at threonine 172; 
Cell Signaling Technology #2535) at a dilution of 1:500 
in 5 percent BSA/TBST, was applied to the other mem-
brane. Membranes incubated overnight at 4°C and then 
vigorously washed three times with 0.1 percent tween in 
TBST for 5 min at room temperature. Membranes were 
treated with Jackson ImmunoResearch (West Grove, PA) 
goat anti-rabbit IgG horseradish peroxidase secondary 
antibody at a dilution of 1:5,000 in 5 percent BSA/TBST 
for 1 hour under dark conditions at room temperature. 
Membranes were washed three times in 0.1 percent tween 
TBST for 5 minutes, washed one time with TBS for 5 
minutes, incubated in Western Blotting Luminol Reagent: 
sc-2048 (Dallas, TX), and finally, exposed to radiograph-
ic film. Blots were quantified with BioRad ImageLab 4.1 
Figure 2. GRMD dogs showed significant variation in phenotype. A) Normal dog (Winthrop) at 6 months of age. 
B) Mildly affected GRMD dog (Lunes) at 6 months of age. Note the mild muscle atrophy of the pelvic limbs (black 
arrows) and mild hyperextension of the carpal joints. C) Severely affected GRMD dog (Kermit) at 6 months. Note the 
prominent joint angle changes and postural deficits, particularly at the carpal, tibiotarsal, stifle, and hip joints, which 
were due to severe muscle weakness/wasting and joint contractures.
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of DMD boys is spared. Similarly, after a period of early 
necrosis, the CS of GRMD dogs regenerates and may un-
dergo paradoxical hypertrophy by 6 months of age. (Fig-
ure 3C) [14,15]. 
Dystrophin-deficient skeletal muscle undergoes my-
ofiber type switching. In further evaluating the molecu-
lar signatures associated with phenotypic variability, we 
evaluated the well characterized switching of fiber types, 
as detected by fiber-type-specific myosin heavy chain 
(MHC) staining [16]. Indeed, we detected reduced fast 
twitch (type II) and increased slow twitch (type I) stain-
ing in both hypertrophied GRMD CS and wasted VL 
muscles compared to normal (Figure 4). 
AMP-kinase (AMPK) modifies the dystrophic pro-
cess at the molecular level. Several studies in the mdx 
mouse have demonstrated a beneficial effect of AMPK 
activation [17-19]. In an analogous way, we found that 
AMPKα phosphorylation (activation) was increased in 
the spared/hypertrophied GRMD CS muscle compared to 
normal dogs (Figures 5A and 5B), while GRMD and nor-
mal levels were comparable in the LDE muscle (wasted 
and measuring half the size of normal in GRMD dogs) 
[14]. Interestingly, we observed a positive correlation 
between phosphoAMPKα and surgically measured CS 
muscle size in GRMD dogs at 6 months of age (Figure 
5C).
Dystrophin-deficient muscle has reduced glycolytic 
and oxidative capacity. Regardless of the molecular path-
way(s) responsible, dystrophic muscle is under a higher 
metabolic demand due to a change in glycolytic and ox-
idative metabolism. The Hoffman laboratory performed 
genome-wide mRNA expression profiling on DMD mus-
cle and found reduced glycolytic and oxidative enzyme 
expression compared to normal, suggesting a secondary 
metabolic defect [7]. Using proteomic profiling via mass 
spectrometry [8], we also detected similar changes in gly-
colytic enzyme expression in the GRMD CS muscle at 
6 months of age, specifically a reduction in phosphoglu-
comutase 1, 6-phosphofructokinase, and glucose-6-phos-
and Gel Doc EZ. PhosphoAMPKα was normalized to 
total AMPKα for normal and GRMD CS and LDE sam-
ples.
Proteomic Profiling. Label-free, quantitative mass 
spectrometry was performed in CS muscle samples from 
three each GRMD and normal dogs at age 4 to 9 weeks 
and 6 months of age, as previously described [8]. 
Statistical Analysis. Prism software version 6 (Graph-
Pad Software, La Jolla, CA) was used for statistical test-
ing and schematic graph generation. A nonparametric 
t-test was used to test significance between GRMD and 
normal dog expression values. A p-value cut-off of 0.05 
was considered statistically significant.
RESULTS
Phenotypic variability in dystrophin deficiency is 
associated with genetic modifiers. Over and above phe-
notypic variation due to in-frame vs. out-of-frame mu-
tations, resulting in variable levels of dystrophin expres-
sion, the secondary effects of dystrophin deficiency can 
lead to striking functional differences in DMD boys. For 
instance, time to wheelchair can vary markedly from 7 to 
17 years of age in the era of glucocorticoid therapy with 
some boys exhibiting severe muscle wasting, weakness, 
and postural deficits, while other boys have a milder phe-
notype (Figure 1) [13]. With regards to animal models, 
dystrophin-deficient GRMD dogs and DMD boys share 
pathogenetic mechanisms. Affected dogs also show phe-
notypic variability, including muscle weakness and pos-
tural abnormalities, despite having the same DMD gene 
mutation (Figure 2) [8]. 
Phenotypic variability is observed among different 
dystrophin deficient muscles. In DMD, GRMD, and mdx, 
histopathological variability occurs at the individual 
muscle level. Most muscles, such as the VL head of the 
quadriceps, undergo progressive dystrophy, with initial 
necrosis followed by immune cell infiltration and fibrosis 
(Figure 3B) [8]. On the other hand, the sartorius muscle 
Figure 3. H&E staining: Muscles from GRMD dogs were variably affected. A) Normal muscle. Note the similar-
sized myofibers, minimal connective tissue, and lack of immune cell infiltration. B) VL muscle of a GRMD dog showed 
degeneration and regeneration (myofiber size variation, black arrow), increased fibrosis and connective tissue, and 
increased immune cell infiltration. C) The CS muscle and its myofibers in GRMD were hypertrophied (black arrow), as 
noted by their increased myofiber diameter compared to GRMD VL and normal muscle. Marker = 50 microns.
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allele, which was associated with a more severe pheno-
type in DMD [22,23]. Given that the genotype seemed 
to alter longitudinal, functional changes in DMD (i.e. a 
faster deterioration of ambulatory function was observed 
with the minor allele) and also increase eccentric con-
traction damage by affecting Sp1 binding sites [24], we 
recommended OPN be considered as a covariate in DMD 
clinical trials [25]. A draft guidance for drug development 
in DMD, initiated by patient advocates and submitted to 
the FDA, suggested that genetic modifiers should be used 
in post-hoc analyses of clinical trial data [26]. Flanigan 
and colleagues described an additional DMD modifier, a 
coding haplotype in LTPB4, which segregated with age at 
loss of ambulation [27]. A more recent exome-chip based 
association study found that a single nucleotide polymor-
phism in the CD40 gene, encoding a T helper costimula-
tory protein, affected function in DMD [28]. Definition of 
complex molecular mechanisms that explain the effects 
of modifier polymorphisms should improve understand-
ing of disease pathophysiology and allow modifier pro-
teins to be manipulated pharmacologically. As an exam-
ple, pharmacological blockade of LTBP4 was suggested 
as a promising therapeutic strategy for fibrotic disorders 
such as DMD [29]. Genome-wide mRNA/microRNA 
expression (Affymetrix chip) and proteomic profiling 
(mass spectrometry) in GRMD dogs from our colony 
phate isomerase (Figure 6). 
Dystrophic myofibers have reduced mitochondrial 
numbers and activity. Given the changes in metabolic 
expression, mitochondrial structure and function was a 
logical area for further inquiry in evaluating oxidative ca-
pacity. In mdx muscle, down-regulation of key metabolic 
enzymes was associated with reduced mitochondria num-
ber and ATP-producing activity; furthermore, mitochon-
dria were reduced in areas where dystrophin was absent 
from the myofiber membrane [20]. In GRMD muscle, we 
also observed fewer than normal and swollen mitochon-
dria in both the hypertrophied CS and wasted VL muscle 
(Figure 7).
DISCUSSION
DMD boys and GRMD dogs have progressive mus-
cle weakness, but phenotypic variability is observed 
among individuals and within different muscle groups 
[2,8]. Although some phenotypic variation can be ex-
plained by the amount of dystrophin expression in muscle 
[2-4], genes outside the DMD gene may modify the dis-
ease process. Giacopelli et al. described a polymorphism 
in the promoter of the SPP1 gene, encoding the cytokine 
osteopontin (OPN), which reduced OPN expression at 
baseline [21]. Pegoraro et al. described the same, minor 
Figure 4. Dystrophin-deficient GRMD dog muscle underwent fiber type switching. In GRMD cranial sartorius 
(CS) and vastus lateralis (VL) muscle, there was reduction in the number of fast staining fibers, while nearly every 
fiber stained with the myosin heavy chain (MHC) slow twitch antibody (gray colors). A: Normal CS: Slow twitch MHC 
staining. B: Normal CS: Fast twitch MHC staining. C: GRMD CS: Slow twitch MHC staining. D: GRMD CS: Fast 
twitch MHC staining. E: Normal VL: Slow twitch MHC staining. F: Normal VL: Fast twitch MHC staining. G: GRMD VL: 
Slow twitch MHC staining. H: GRMD VL: Fast twitch MHC staining. All dogs shown at ~6 months of age. Images A-D 
were 3X3 stitched 4X objective images displaying the entire muscle biopsy sections. Images E-H were single images 
collected with a 4X objective. Outlined white areas highlight representative serially sectioned muscle fascicles used 
for identifying slow and fast twitch fiber type variation. White arrows indicate serially sectioned area in the GRMD VL 
that had increased slow twitch staining.
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species barriers and influence the DMD phenotype was 
provided by identification of the LTBP4 locus in a del-
ta-sarcoglycan deficient mouse strain, carrying a 36 bp 
insertion/deletion [35], before a different modifier haplo-
type was identified in the homologous human gene [27].
In DMD and its animal models, phenotypic variabil-
ity occurs at the histopathological level. In the GRMD 
dog, this differential muscle involvement is thought to 
arise at least partially from the opposing of flexors versus 
extensor muscles, with the former being affected early 
in life, as the animal crawls, and the latter spared [36]. 
As the individual begins to ambulate, extensors become 
more affected. An alternative, not mutually exclusive ex-
planation might be that specific muscles have peculiar 
fiber type composition, innervation, and gene expression 
patterns. This is intriguing from a therapeutic standpoint; 
identifying molecular signatures associated with muscle 
sparing/hypertrophy could provide molecular targets for 
therapeutic development [8,37]. 
In further evaluating the molecular signatures asso-
ciated with muscle hypertrophy versus wasting in dys-
trophin deficiency, changes in muscle metabolism are of 
great interest to our lab. As such, evaluating myofiber 
type composition would be a logical first step. Type II 
(fast-twitch) fibers seem to be preferentially affected (and 
reduced in number) in dystrophin-deficient muscle, most 
likely due to reduced oxidative-phosphorylative and in-
creased glycolytic capacity of these fiber types. On the 
other hand, type I (slow twitch) fibers have increased ox-
idative capacity, are relatively spared and even increased 
in number compared to type II, suggesting a metabolic 
switch from glycolytic to oxidative metabolism [16]. 
We showed in this study that GRMD dogs undergo fiber 
switching from fast to slow twitch, but no obvious differ-
ences between hypertrophied and wasted muscle. In the 
GRMD (CXMD
J
) Japanese colony, perpetuated from a 
descendent of our colony, researchers also showed type 
II to I fiber type switching in dystrophic muscle [38]. In 
demonstrated that SPP1 was associated with several key 
molecular pathways and could serve as a biomarker for 
progression [11,30]. Although the SPP1 promoter has 
not been evaluated in a similar fashion in GRMD dogs, 
we believe osteopontin significantly modifies the disease 
process. Taken together, these studies strongly suggest 
that genetic modifiers influence the phenotype of dystro-
phin deficient individuals.
This phenotypic variation confounds assessment of 
outcome parameters in preclinical trials, which are typi-
cally conducted between 3 and 6 months of age [10,29], 
a period that corresponds to ages 5 to 10 years in DMD 
[31,32]. Dogs enrolled in these studies are humanely eu-
thanized at 6 months of age. However, a number of mild-
ly affected GRMD dogs are maintained beyond 6 months 
for use as breeders. We retrospectively evaluated our en-
tire GRMD colony perpetuated over years and observed 
phenotypes ranging from near normal appearance and 
muscle strength to a fulminating deadly neonatal disor-
der [33]. In particular, mildly affected GRMD dogs that 
have lived 3 years of age or greater were characterized. 
With regard to genetic modifiers, a recent study from a 
Brazilian GRMD colony identified a Jagged1 polymor-
phism in so-called “escaper” GRMD dogs that lived to 
9 years of age and contrasted their genetic profile with 
a group of dogs that died before 5 years [34]. The study 
concluded that the Jagged1 polymorphism contributed 
to the mild phenotype, presumably because of enhanced 
muscle regeneration. However, none of the mildly affect-
ed GRMD dogs from our colony for which DNA sam-
ples were available had the Jagged1 polymorphism. This 
is not surprising in that the Jagged1 mutation identified 
in the Brazilian colony traced to an outcross and would 
not be expected in other colonies. As indicated by our 
earlier studies, other genetic modifiers such as osteopon-
tin, myostatin, dystroglycan, and myotrophin are prob-
ably associated with phenotypic variability in GRMD 
dogs [8,10,30]. Proof of concept that modifiers can cross 
Figure 5. The hypertrophied CS muscle had increased phosphorylated (P) AMPKα compared to normal. A) 
Note the variability in western blot expression of P-AMPKα in GRMD dog samples. B) P-AMPKα was normalized 
to Total AMPKα protein and increased compared to normal samples. * = p < 0.05. C) P-AMPKα was positively 
correlated with CS circumference.
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activation may have a protective and even beneficial ef-
fect in dystrophic muscle. Further studies are underway 
to activate AMPK in the GRMD dog and evaluate chang-
es in phenotype and downstream molecular signatures.
The accumulating data outline the increased meta-
bolic demand that occurs secondarily to dystrophin de-
ficiency. Chen and colleagues evaluated microarray pro-
files of DMD muscle and found reduced glycolytic and 
oxidative metabolism genes [7]. In mdx mice, there was 
a reduction in lactate dehydrogenase (marker for glyco-
lytic enzyme) activity [9]. We also showed in this study 
several glycolytic enzymes reduced at the protein level in 
GRMD muscle, as detected by proteomic profiling and 
mass spectrometry [8]. Terrill and colleagues revealed 
this glycolytic/oxidative phosphorylative enzyme reduc-
tion was due to protein thiol oxidation [41]. A quantita-
tive proteomic profile of GRMD versus normal muscle 
confirmed a defect of metabolic proteins, many regulated 
by PGC-1α [42]. 
In further evaluating metabolic capacity, we evaluat-
ed mitochondria localization in GRMD muscles. The ATP 
producing organelles are normally dispersed throughout 
myofibers and interface with the sarcolemmal membrane 
[43]. A recent study by Percival and colleagues showed a 
reduction in mitochondria in mdx mice and suggested the 
metabolic defect was directly related to dystrophin defi-
ciency [20]. We also observed reduced and swollen mito-
chondria in both dystrophin-deficient hypertrophied and 
wasted muscle. A recent study evaluated muscle damage 
induced by cardiotoxin injection and showed similar 
histopathological, ultrastructural, and metabolic profiles 
compared to dystrophic muscle [44]. Indeed, the reduced 
glycolytic enzyme expression and mitochondria observed 
in our GRMD dogs may be due to the inflammation and 
healthy animals, cross-innervation of muscles with alpha 
motor neurons of an opposing nerve resulted in fiber type 
switching [39]. In dystrophic muscle, the molecular sig-
natures responsible for the fast to slow switch are mediat-
ed, in part, by the folliculin interacting protein-1 (fnip-1) 
– AMPK pathway [40].
In the context of phenotypic variability at the mus-
cle level, we showed that phosphorylated AMPKα1- and 
-α2 are increased in hypertrophied muscle. Moreover, 
P-AMPK was directly correlated with surgically mea-
sured CS muscle size, suggesting the energy sensor ki-
nase may promote muscle hypertrophy. These data are 
supported by the fact that the wasted LDE, a muscle mea-
suring half its normal size in GRMD dogs [14], showed 
similar phosphoAMPKα expression compared to normal 
muscle. Pharmacological activation of the kinase was 
associated with neuronal nitric oxide synthase (nNOS) 
activation and increased nitric oxide production in mdx 
mouse cardiomyocytes [17]. The authors suggested that 
the mechanical stretch-mediated AMPK phosphorylation 
of nNOS was dependent on an intact DGC; pharmaco-
logical activation of AMPK in dystrophin-deficient mdx 
muscle restored this function [17]. Indeed, another study 
in mdx mice showed that administration of the AMPK 
activator, metformin, increased downstream expression 
of several muscle proteins, including peroxisome prolif-
erator-activated receptor Ɣ Co-activator 1α and the dys-
trophin homologue utrophin [18]. Providing further evi-
dence of the importance of AMPKα1, mdx mice treated 
with the AMPK agonist, 5-aminoimidazole-4-carboxam-
ide-1-β-D-ribofuranoside (AICAR) had improved func-
tion, reduced creatine kinase levels, and increased oxida-
tive metabolism proteins [19]. The previous mdx studies 
and the GRMD data presented here suggest that AMPKα 
Figure 6. Glycolytic enzymes were reduced in hypertrophied GRMD CS muscle at 6 months of age compared 
to normal. Phosphoglucomutase-1, 6-phophofructokinase, and glucose-6-phosphate isomerase were reduced at 6 
months (M) in GRMD cranial sartorius (CS) (black bars) compared to normal (white bars). There was not a significant 
change at 4 to 9 weeks (W). N = 3 for each group. Total spectral counts were used to determine relative abundance.  
* = P < 0.05; ** p < 0.01; *** p < 0.001.
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